EFHD2

Across TCGA pan-cancer cohorts, EFHD2 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of EFHD2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where EFHD2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types EFHD2 is over-expressed in tumor, although a few such as PRAD show the opposite, repressed pattern.

KIRC, HNSC, and KIRP are the cancer types where EFHD2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in EFHD2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	IV	+1.865	<.001	12	view →
HNSC	Male	All	+1.130	<.001	9	view →
KIRP	Male	All	+0.803	<.001	9	view →
THCA	Female	II,III,IV	+1.487	<.001	7	view →
STAD	Male	II,III,IV	+1.520	<.001	6	view →
LIHC	Female	II,III,IV	+1.165	<.001	6	view →
BRCA	Female	All	+0.410	<.001	6	view →
CHOL	All	All	+1.622	<.001	3	view →
ESCA	All	All	+1.116	.008	3	view →
PRAD	All	All	−0.481	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

EFHD2–KIRC

Open the KIRC breakdown →